Navigation Links

This release is available in German.

Diagnosis and treatment in one go: Korean researchers led by Tae Gwan Park and Jinwoo Cheon have developed the basis for a four-in-one agent that can detect, target, and disable tumor cells while also making them macroscopically and microscopically visible. As they report in the journal Angewandte Chemie, their work involves magnetic iron oxide particles with a fluorescence dye, RNA fragments, and a special peptide attached. The peptide is present to specifically identify the cancer cells; the RNA fragments suppress the special cancer-cell genes, killing the cells. The magnetic particles act as a contrast agent for magnetic resonance imaging, and the fluorescence dye allows for microscopic imaging of the target cells.

In order to build a protein according to the genetic information in a cell, the gene on the DNA is read off and translated into a "stencil", mRNA, which is then used by the cell as a blueprint for the protein. The mRNA is a good point of attack to stop the synthesis of proteins required for tumor growth. To achieve this, siRNAs (small interfering RNAs) are introduced into the cell. These are short, double-stranded RNA fragments that bind specifically to the target mRNA. Inside the cell, a special protein complex binds to the siRNA, which unwinds and cleaves the mRNA. In this unprotected form, the mRNA is rapidly degraded by the cell.

When bound to nanoparticles, the siRNAs are easier to slip into cells. In order to specifically target cancer cells, the particles carry a short peptide, called RGD, which points the way: RGD strongly binds to an integrin, a membrane protein that is anchored to metastasizing tumor cells in much higher amounts than in healthy tissue. The integrins with RGD-equipped nanoparticles are actively brought into the cell interior with their cargo intact (receptor-mediated endocytosis).

The magnetic particles not only act as an aide for transport, they are also a contrast agent for MRI. This reveals where the tumors are, whether the particles are concentrating there, and how the treatment is progressing. If higher resolution is required, the fluorescence dye molecules come into play. In histological slides of tissue samples, they make it possible to see how the magnetic particles are taken up by individual cells an in which cell compartments they are concentrated.


Contact: Jinwoo Cheon

Post Your Comments:
(Date:12/1/2015)... (PRWEB) , ... December 02, 2015 , ... ... research “ Gastrointestinal events and association with initiation of treatment for osteoporosis ”. ... the use of pharmacological treatment in patients diagnosed with osteoporosis. Based on a ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... its acquisition by Jordan Industries International, LLC (“JII”). , With support from JII, ... and maintenance services to hospitals, surgery centers, clinics, research labs and medical facilities ...
(Date:12/1/2015)... ... , ... According to an article published on November 16th by ... U.S. Department of Health and Human Services, claiming that any states which do not ... clause in the law prohibiting the denial of coverage for pre-existing conditions. The article ...
(Date:12/1/2015)... ... December 01, 2015 , ... Baptist Medical Center Jacksonville ... is the only hospital in the region providing what is known as the ... pacing patients were revealed recently at a medical conference and published in The ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Paul Vitenas, one of ... has been named by MedEsthetics magazine as the Best Single Physician Practice in the ... the many elite aesthetic physicians honored by the industry publication. , Dr. Vitenas ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , Dec. 1, 2015 Relmada Therapeutics, Inc. ... treatment of chronic pain, announced today that the company will ... be held December 1-3 at the Luxe Sunset Boulevard Hotel ... Traversa , CEO of Relmada Therapeutics, will present on Thursday, ... Time). . Please register at least 10 ...
(Date:12/1/2015)... 2015 CytRx Corporation (NASDAQ: CYTR ), ... today announced that it has reached its enrollment target ... 3 clinical trial of aldoxorubicin in patients with previously ... be completed in Q1 2016. The Phase 3 trial is ... Protocol Assessment from the FDA at 79 sites in ...
(Date:12/1/2015)... , Dec. 1, 2015  Today, ... the launch of CareFront, a first-of-its-kind population health ... diagnosed with cancer. Designed to be built into ... cancer patients with resources for their care and ... program also offers tools to help patients understand ...
Breaking Medicine Technology: